For patients with acute and subacute ILD, including those with anti-MDA5 antibody-positive DM and ASS, high-dose GCs should be combined with CNIs (Fujisawa, 2021; Fujisawa et al., 2021; Chen et al., 2022). Here, IFIH1 is linked to interstitial lung disease.